<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03206801</url>
  </required_header>
  <id_info>
    <org_study_id>B2017:076</org_study_id>
    <secondary_id>364003</secondary_id>
    <secondary_id>TMCT-04</secondary_id>
    <nct_id>NCT03206801</nct_id>
  </id_info>
  <brief_title>Urine CXCL10 Monitoring Trial in Kidney Transplant</brief_title>
  <official_title>A Randomized Controlled Trial of Urine CXCL10 Chemokine Monitoring Post-renal Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian National Transplant Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II-III multi-center prospective randomized controlled clinical trial of
      incident adult renal transplant patients.

      The primary objective of this study is to determine if the early treatment of rejection, as
      detected by urinary CXCL10, will improve renal allograft outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II-III multi-center prospective randomized controlled clinical trial of
      incident adult renal transplant patients. Patients will be screened for eligibility (n≈485)
      and n≈420 will be enrolled and undergo post-transplant surveillance with urinary CXCL10. Two
      hundred and fifty patients deemed at high risk for rejection based on a confirmed elevated
      urine CXCL10 will undergo 1:1 randomization to the intervention and control arms, stratified
      by center. The total study duration is approximately 5 years; and there two main phases -
      screening and intervention.

      All eligible, enrolled patients will undergo the Screening Phase (n≈420). Routine urine
      CXCL10 screening will be done from 2 weeks - 9 months post-transplant. We have previously
      shown that urine CXCL10 is elevated in ischemia-reperfusion injury, so screening will
      commence at 2 weeks (+/- 4 days) to exclude this as a potential confounding factor (60).

      If patient develops a confirmed elevated urine CXCL10 level and is considered high risk for
      rejection, they will proceed to Randomization in the Intervention Phase, which can occur
      anytime between 2 weeks - 9 months post-transplant. Participants in the Intervention Arm will
      undergo renal biopsy to check for rejection. Biopsy-proven subclinical rejection will be
      treated per study protocol. Participants in the Control Arm will continue routine
      post-transplant surveillance with serum creatinine and proteinuria; serial urine samples will
      continue to be collected and analyzed (blinded), but not used to direct care. All randomized
      participants will undergo a 12-month study exit visit with protocol biopsy to determine
      primary, secondary and long-term outcomes.

      Enrolled patients with persistently low urine CXCL10 and low risk of rejection from 2 weeks -
      9 months post-transplant will be considered Off-Study (not randomized). They will undergo a
      12-month study exit visit (+/- 7 days) to determine secondary and long-term outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a Phase II-III multi-center prospective randomized controlled clinical trial of incident adult renal transplant patients. Patients with elevated urine CXCL10 will be randomized 1:1 to the intervention and control arms, stratified by center (~ 420 enrolled to urine CXCL10 screening for n=250 randomized participants).</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The assessor of the primary outcome will be masked. As the intervention involves a study biopsy, based on an elevated urine CXCL10, it is not possible to blind the participant, care provider or investigator.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Death-censored graft loss</measure>
    <time_frame>2 weeks-12 months post-transplant</time_frame>
    <description>Return to dialysis or re-transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical indication biopsy-proven acute rejection</measure>
    <time_frame>2 weeks-12 months post-transplant</time_frame>
    <description>Clinical rejection, Banff criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>De novo donor specific antibody development</measure>
    <time_frame>2 weeks-12 months post-transplant</time_frame>
    <description>De novo human leukocyte antibody (HLA) antibodies, donor specific</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subclinical tubulitis</measure>
    <time_frame>12-month study exit biopsy</time_frame>
    <description>Subclinical rejection, Banff criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interstitial fibrosis and inflammation (IFTA + i)</measure>
    <time_frame>12-month study exit biopsy</time_frame>
    <description>IFTA + i, defined by Mayo criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal allograft function</measure>
    <time_frame>6, 12, 24 and 60 months post-transplant</time_frame>
    <description>Change in eGFR (slope, ∆) and graft function (eGFR) (absolute, mL/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular inflammation</measure>
    <time_frame>12-month study exit biopsy</time_frame>
    <description>Banff ptc, g, c4d, cg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development IFTA from implantation to 12-months</measure>
    <time_frame>12-month study exit biopsy</time_frame>
    <description>Banff ∆ ci, ct, cv</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days from transplantation to clinical-biopsy proven rejection</measure>
    <time_frame>2 weeks-12 months post-transplant</time_frame>
    <description>Time to biopsy proven rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albuminuria &gt;300mg/day</measure>
    <time_frame>6, 12, 24 and 60 months post-transplant</time_frame>
    <description>Urine albumin: Cr ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of urine CXCL10 monitoring strategy</measure>
    <time_frame>2 weeks-12 months post-transplant</time_frame>
    <description>Costs of urine CXCL10 screening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 and 12 months post-transplant</time_frame>
    <description>EuroQOL (EQ-5DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine CXCL10 kinetics</measure>
    <time_frame>2 weeks-12 months post-transplant</time_frame>
    <description>Change in urine CXCL10 levels in response to rejection therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Kidney Transplant; Complications</condition>
  <condition>Rejection of Renal Transplant</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with high urine CXCL10 randomized to the Intervention Arm will undergo a kidney transplant biopsy to check for rejection. Biopsy-proven subclinical rejection will be treated per study protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants with high urine CXCL10 randomized to the Control Arm will continue routine post-transplant surveillance with serum creatinine and proteinuria; serial urine samples will continue to be collected and analyzed (blinded), but not used to direct care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Kidney transplant biopsy</intervention_name>
    <description>Elevated urine CXCL10 will trigger a study biopsy in patients randomized to the intervention arm. Subclinical rejection will be treated per protocol.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Protocol biopsy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants must be able to understand and provide written informed consent

          2. Stated willingness to comply with all study procedures and availability for the
             duration of the study

          3. All ethnic and gender groups will have equal access to the study

          4. Incident adult (age ≥18) renal transplant patients with a living or deceased donor
             kidney transplant

          5. Confirmed elevated urine CXCL10:Cr without a urinary tract infection or menses.

        Exclusion Criteria:

          1. Primary non-function

          2. Blood group (ABO) incompatible

          3. Pre-transplant donor specific antibody (DSA) positive

          4. Human leukocyte (HLA) 0 HLA antigen D-related (DR) and 0 major HLA class 2 (DQ)
             mis-match

          5. Presence of other transplanted organ or co-transplanted organ

          6. Active infection at the time of randomization

          7. Followed outside of investigational center

          8. Participation in other interventional trials within 4-weeks post-transplant or anytime
             post-transplant till study end at 12-months

          9. Intention to not use a maintenance immunosuppression regimen consisting of calcineurin
             inhibitor (CNI) and anti-proliferative agents

         10. Any condition that, in the opinion of the investigator, would pose risk to the
             subject's safe participation, or interfere with their ability to comply with the study
             requirements, or may impact the quality of interpretation of the data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Ho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brendon Foot, BA, CCRP</last_name>
    <phone>204-770-7154</phone>
    <email>bfoot@wrha.mb.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kiran Sran, MSc</last_name>
    <phone>204-787-3618</phone>
    <email>ksran2@exchange.hsc.mb.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bronwyn Hockley</last_name>
      <phone>61 8 7074 3077</phone>
      <email>bronwyn.hockley@sa.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Meg Hockley</last_name>
      <phone>61 8 7074 5780</phone>
      <email>meg.hockley@sa.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Carroll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Manitoba, Transplant Manitoba Adult Kidney Program</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Lesyk, RN, BN</last_name>
      <phone>204-787-8590</phone>
      <email>mlesyk@hsc.mb.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kiran Sran, MSc</last_name>
      <phone>204-787-3618</phone>
      <email>ksran2@hsc.mb.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Julie Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Nickerson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Rush, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chris Wiebe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ian Gibson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Université Laval</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>France Samson</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>15195</phone_ext>
      <email>france.samson@chuq.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Danielle Villeneuve</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>16487</phone_ext>
      <email>danielle.villeneuve@mail.chuq.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sacha De Serres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Ho J, Rush DN, Karpinski M, Storsley L, Gibson IW, Bestland J, Gao A, Stefura W, HayGlass KT, Nickerson PW. Validation of urinary CXCL10 as a marker of borderline, subclinical, and clinical tubulitis. Transplantation. 2011 Oct 27;92(8):878-82. doi: 10.1097/TP.0b013e31822d4de1.</citation>
    <PMID>21876477</PMID>
  </results_reference>
  <results_reference>
    <citation>Hirt-Minkowski P, Amico P, Ho J, Gao A, Bestland J, Hopfer H, Steiger J, Dickenmann M, Burkhalter F, Rush D, Nickerson P, Schaub S. Detection of clinical and subclinical tubulo-interstitial inflammation by the urinary CXCL10 chemokine in a real-life setting. Am J Transplant. 2012 Jul;12(7):1811-23. doi: 10.1111/j.1600-6143.2012.03999.x. Epub 2012 Mar 5.</citation>
    <PMID>22390571</PMID>
  </results_reference>
  <results_reference>
    <citation>Blydt-Hansen TD, Gibson IW, Gao A, Dufault B, Ho J. Elevated urinary CXCL10-to-creatinine ratio is associated with subclinical and clinical rejection in pediatric renal transplantation. Transplantation. 2015 Apr;99(4):797-804. doi: 10.1097/TP.0000000000000419.</citation>
    <PMID>25222013</PMID>
  </results_reference>
  <results_reference>
    <citation>Hirt-Minkowski P, Ho J, Gao A, Amico P, Koller MT, Hopfer H, Rush DN, Nickerson PW, Schaub S. Prediction of Long-term Renal Allograft Outcome By Early Urinary CXCL10 Chemokine Levels. Transplant Direct. 2015 Sep 24;1(8):e31. doi: 10.1097/TXD.0000000000000537. eCollection 2015 Sep.</citation>
    <PMID>27500231</PMID>
  </results_reference>
  <results_reference>
    <citation>Hirt-Minkowski P, Rush DN, Gao A, Hopfer H, Wiebe C, Nickerson PW, Schaub S, Ho J. Six-Month Urinary CCL2 and CXCL10 Levels Predict Long-term Renal Allograft Outcome. Transplantation. 2016 Sep;100(9):1988-96. doi: 10.1097/TP.0000000000001304.</citation>
    <PMID>27548845</PMID>
  </results_reference>
  <results_reference>
    <citation>Ho J, Sharma A, Mandal R, Wishart DS, Wiebe C, Storsley L, Karpinski M, Gibson IW, Nickerson PW, Rush DN. Detecting Renal Allograft Inflammation Using Quantitative Urine Metabolomics and CXCL10. Transplant Direct. 2016 May 19;2(6):e78. doi: 10.1097/TXD.0000000000000589. eCollection 2016 Jun.</citation>
    <PMID>27500268</PMID>
  </results_reference>
  <results_reference>
    <citation>Ho J, Rush DN, Krokhin O, Antonovici M, Gao A, Bestland J, Wiebe C, Hiebert B, Rigatto C, Gibson IW, Wilkins JA, Nickerson PW. Elevated Urinary Matrix Metalloproteinase-7 Detects Underlying Renal Allograft Inflammation and Injury. Transplantation. 2016 Mar;100(3):648-54. doi: 10.1097/TP.0000000000000867.</citation>
    <PMID>26906940</PMID>
  </results_reference>
  <results_reference>
    <citation>Hricik DE, Nickerson P, Formica RN, Poggio ED, Rush D, Newell KA, Goebel J, Gibson IW, Fairchild RL, Riggs M, Spain K, Ikle D, Bridges ND, Heeger PS; CTOT-01 consortium. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant. 2013 Oct;13(10):2634-44. doi: 10.1111/ajt.12426. Epub 2013 Aug 22.</citation>
    <PMID>23968332</PMID>
  </results_reference>
  <results_reference>
    <citation>Rabant M, Amrouche L, Lebreton X, Aulagnon F, Benon A, Sauvaget V, Bonifay R, Morin L, Scemla A, Delville M, Martinez F, Timsit MO, Duong Van Huyen JP, Legendre C, Terzi F, Anglicheau D. Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection. J Am Soc Nephrol. 2015 Nov;26(11):2840-51. doi: 10.1681/ASN.2014080797. Epub 2015 May 6.</citation>
    <PMID>25948873</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urine biomarker</keyword>
  <keyword>CXCL10 chemokine</keyword>
  <keyword>Post-transplant monitoring</keyword>
  <keyword>Protocol biopsy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

